Samjin Pharmaceutical announced on the 29th that it has decided to invest 1 billion KRW in Neurofit, a specialized company in brain disease imaging artificial intelligence (AI) solutions, and held a related agreement ceremony.
Choi Yong-ju, CEO of Samjin Pharmaceutical (left), and Bin Jun-gil, CEO of Neurofit, are posing for a commemorative photo at the strategic investment and business agreement ceremony. [Photo by Samjin Pharmaceutical]
Neurofit is a specialized company that researches and develops AI-based brain imaging analysis solutions covering the entire cycle of brain disease diagnosis, treatment guidance, and therapy. To advance the development of new drugs and treatment technologies for Alzheimer's dementia, it actively participates in global clinical trials related to these diseases by utilizing brain imaging analysis technology. Samjin Pharmaceutical confirmed Neurofit's technological competitiveness and growth potential and proceeded with a total investment of 1 billion KRW as a strategic investor (SI).
Going forward, the two companies plan to combine Samjin Pharmaceutical's research resources, infrastructure, and network with Neurofit's brain imaging analysis technology to create mutual synergy and drive product commercialization, aiming to produce tangible results.
Choi Yong-ju, CEO of Samjin Pharmaceutical, said, "We are pleased to welcome Neurofit, which has excellent technology in brain imaging analysis, as a strategic partner," adding, "We will actively support this investment as a starting point to continue a long-term cooperative relationship." Bin Jun-gil, CEO of Neurofit, also stated, "By connecting Neurofit's products and technologies with Samjin Pharmaceutical's extensive infrastructure and network, we will be able to create new growth engines," and added, "We will do our utmost to achieve business success in the field of brain diseases such as dementia and stroke for both companies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
